Zacks Research Forecasts Moderna's Q2 Earnings (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Equities researchers at Zacks Research dropped their Q2 2025 earnings estimates for Moderna in a note issued to investors on Wednesday, May 21st. Zacks Research analyst S. Ganoria now anticipates that the company will earn ($3.26) per share for the quarter, down from their previous estimate of ($3.10). The consensus estimate for Moderna's current full-year earnings is ($9.61) per share. Zacks Research also issued estimates for Moderna's Q3 2025 earnings at ($2.09) EPS, Q4 2025 earnings at ($2.67) EPS, Q1 2026 earnings at ($2.26) EPS, Q2 2026 earnings at ($2.84) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($8.18) EPS, Q1 2027 earnings at ($1.88) EPS and FY2027 earnings at ($4.43) EPS.

Other research analysts also recently issued research reports about the stock. Barclays reduced their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. UBS Group dropped their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, Evercore ISI dropped their target price on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $53.58.

Moderna Stock Up 1.9%

MRNA stock traded up $0.50 during trading on Monday, hitting $26.76. The company had a trading volume of 14,584,904 shares, compared to its average volume of 8,035,408. The firm has a market capitalization of $10.35 billion, a P/E ratio of -2.88 and a beta of 1.99. Moderna has a 52-week low of $23.15 and a 52-week high of $164.73. The company has a 50 day simple moving average of $26.83 and a 200-day simple moving average of $34.20.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm's revenue was down 35.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.07) EPS.

Institutional Trading of Moderna

A number of institutional investors have recently modified their holdings of the company. Exchange Traded Concepts LLC grew its position in Moderna by 48.9% during the 4th quarter. Exchange Traded Concepts LLC now owns 26,137 shares of the company's stock worth $1,087,000 after purchasing an additional 8,579 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after buying an additional 388 shares during the last quarter. Forsta AP Fonden raised its holdings in shares of Moderna by 0.7% in the fourth quarter. Forsta AP Fonden now owns 69,400 shares of the company's stock worth $2,886,000 after buying an additional 500 shares during the last quarter. Swedbank AB raised its holdings in shares of Moderna by 11.3% in the fourth quarter. Swedbank AB now owns 94,685 shares of the company's stock worth $3,937,000 after buying an additional 9,586 shares during the last quarter. Finally, EMC Capital Management raised its holdings in shares of Moderna by 311.2% in the fourth quarter. EMC Capital Management now owns 1,250 shares of the company's stock worth $52,000 after buying an additional 946 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.